Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer

Cancer Chemotherapy and Pharmacology

Volumn 75, Issue 6, 2015, Pages 1135-1141

  Kordes, S ^a   Klumpen H J ^a   Weterman, M J ^a   Schellens, J H M ^b,c   Richel, D J ^a   Wilmink, J W ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Capecitabine; Everolimus; mTOR; Pancreatic cancer; Phase II; Targeted therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CAPECITABINE; EVEROLIMUS; GAMMA GLUTAMYLTRANSFERASE; GEMCITABINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; FLUOROURACIL; MTOR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ACINAR CELL CARCINOMA; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANKLE EDEMA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APHTHOUS STOMATITIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; DIARRHEA; DRUG SAFETY; EPISTAXIS; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; HYPONATREMIA; INFECTION; KIDNEY FUNCTION; LIVER FUNCTION; MALE; MIDDLE AGED; MUCOSA INFLAMMATION; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; PIGMENT DISORDER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; SKIN PRURITUS; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; METABOLISM; MORTALITY; PANCREATIC NEOPLASMS;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAPECITABINE; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; EVEROLIMUS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; SIROLIMUS; SURVIVAL RATE; TOR SERINE-THREONINE KINASES;

EID: 84929709767     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-015-2730-y     Document Type: Article

References (39)

1. Faivre S, Kroemer G, Raymond E (2006) Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5(8):671-688
2. LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA (2008) Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 11(1-2):32-50
3. Aoki M, Blazek E, Vogt PK (2001) A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci USA 98(1):136-141
4. Matsuzaki T, Yashiro M, Kaizaki R, Yasuda K, Doi Y, Sawada T et al (2009) Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer. Cancer Sci 100(12):2402-2410
5. Bu X, Le C, Jia F, Guo X, Zhang L, Zhang B et al (2008) Synergistic effect of mTOR inhibitor rapamycin and fluorouracil in inducing apoptosis and cell senescence in hepatocarcinoma cells. Cancer Biol Ther 7(3):392-396
6. Seeliger H, Guba M, Koehl GE, Doenecke A, Steinbauer M, Bruns CJ et al (2004) Blockage of 2-deoxy-D-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy. Clin Cancer Res 10(5):1843-1852
7. Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O'Reilly T et al (2005) The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120(6):747-759
8. Seeliger H, Guba M, Kleespies A, Jauch KW, Bruns CJ (2007) Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev 26(3-4):611-621
9. Mabuchi S, Altomare DA, Cheung M, Zhang L, Poulikakos PI, Hensley HH et al (2007) RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 13(14):4261-4270
10. Khariwala SS, Kjaergaard J, Lorenz R, Van Lente F, Shu S, Strome M (2006) Everolimus (RAD) inhibits in vivo growth of murine squamous cell carcinoma (SCC VII). Laryngoscope 116(5):814-820
11. Zitzmann K, De Toni EN, Brand S, Goke B, Meinecke J, Spottl G et al (2007) The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 85(1):54-60
12. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449-456
13. Amato RJ, Jac J, Giessinger S, Saxena S, Willis JP (2009) A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 115(11):2438-2446
14. Wolpin BM, Hezel AF, Abrams T, Blaszkowsky LS, Meyerhardt JA, Chan JA et al (2009) Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol 27(2):193-198
15. Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S et al (2009) Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 27(27):4536-4541
16. Soria JC, Shepherd FA, Douillard JY, Wolf J, Giaccone G, Crino L et al (2009) Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol 20(10):1674-1681
17. O'Donnell A, Faivre S, Burris HA III, Rea D, Papadimitrakopoulou V, Shand N et al (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26(10):1588-1595
18. Okamoto I, Doi T, Ohtsu A, Miyazaki M, Tsuya A, Kurei K et al (2010) Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors. Jpn J Clin Oncol 40(1):17-23
19. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K et al (2008) Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26(10):1603-1610
20. Campone M, Levy V, Bourbouloux E, Berton Rigaud D, Bootle D, Dutreix C et al (2009) Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours. Br J Cancer 100(2):315-321
21. Andre F, Campone M, O'Regan R, Manlius C, Massacesi C, Sahmoud T et al (2010) Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol 28(34):5110-5115
22. Pacey S, Rea D, Steven N, et al (2004) Results of a phase 1 clinical trial investigation a combination of the oral mTOR-inhibitor Everolimus (E, RAD001) and Gemcitabine (GEM) in patients (pts) with advanced cancers. In: Abstract ASCO annual meeting 2004, J Clin Oncol 22 (Suppl. 14):3120
23. Milton DT, Riely GJ, Azzoli CG, Gomez JE, Heelan RT, Kris MG et al (2007) Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. Cancer 110(3):599-605
24. Hainsworth JD, Infante JR, Spigel DR, Peyton JD, Thompson DS, Lane CM et al (2010) Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer 116(17):4122-4129
25. Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J et al (2009) Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27(16):2630-2637
26. Lee SJ, Lee J, Lee J, Park SH, Park JO, Park YS et al (2013) Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients. Invest New Drugs 31(6):1580-1586
27. Deenen MJ, Klumpen HJ, Richel DJ, Sparidans RW, Weterman MJ, Beijnen JH et al (2011) Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies. Invest New Drugs 30(4):1557-1565
28. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817-1825
29. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6):2403-2413
30. Cartwright TH, Cohn A, Varkey JA, Chen YM, Szatrowski TP, Cox JV et al (2002) Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 20(1):160-164
31. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205-216
32. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). http://ctep.cancer.gov/reporting/ctc-v30.html
33. Gehan EA (1961) The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis. 13:346-353
34. Bodoky G, Timcheva C, Spigel DR, La Stella PJ, Ciuleanu TE, Pover G et al (2011) A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest New Drugs 30(3):1216-1223
35. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van CE et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364(6):514-523
36. Labori KJ, Hjermstad MJ, Wester T, Buanes T, Loge JH (2006) Symptom profiles and palliative care in advanced pancreatic cancer: a prospective study. Support Care Cancer 14(11):1126-1133
37. Cassidy J, Twelves C, Van CE, Hoff P, Bajetta E, Boyer M et al (2002) First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13(4):566-575
38. Punt CJ, Boni J, Bruntsch U, Peters M, Thielert C (2003) Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Ann Oncol 14(6):931-937
39. Joka M, Boeck S, Zech CJ, Seufferlein T, Wichert GV et al (2014) Combination of antiangiogenic therapy using the mTOR-inhibitor everolimus and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer: a dose-finding study. Anticancer Drugs 25(9):1095-1101